DEF: Harvard Apparatus Regenerative Technology Annual Meeting Proxy

Harvard Apparatus Regenerative Technology, Inc. is holding its 2026 Annual Meeting of Stockholders on June 18, 2026, to elect directors, ratify auditors, and vote on executive compensation.

Summary

• The company is holding its Annual Meeting of Stockholders on June 18, 2026, at its Holliston, MA headquarters.
• Key proposals include the election of three directors for one-year terms, ratification of CBIZ CPAs P.C. as independent auditors for fiscal year 2026, and a non-binding advisory vote on executive compensation.
• The Board of Directors recommends voting FOR all proposals.
• The record date for determining eligible stockholders is April 21, 2026.
• Proxy materials are being furnished to stockholders over the internet, with a Notice of Internet Availability mailed on or about May 6, 2026.
• The company is a smaller reporting company and complies with reduced disclosure requirements.
• The filing details director compensation, executive compensation, and outstanding equity awards as of December 31, 2025.
• It also outlines the company's Code of Business Conduct and Ethics, and its Insider Trading Policy.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to the mention of substantial doubt about the company's ability to continue as a going concern in the prior year's audit report, despite the routine nature of the proxy statement's proposals.

Positives

• The company is holding its annual meeting as scheduled, indicating ongoing operational and governance processes.
• The Board of Directors is recommending favorable votes for director nominees, auditor ratification, and executive compensation, suggesting internal confidence.
• Independent directors comprise the Audit, Compensation, and Governance committees, adhering to good governance practices.
• The company has a Code of Business Conduct and Ethics and an Insider Trading Policy in place.
• The Audit Committee is actively involved in overseeing the independent auditors and financial reporting.
• Director compensation includes stock options, aligning their interests with shareholders.

Negatives

• The company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, contains an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern, as noted in the auditor's report.
• The company is a smaller reporting company, which implies potentially less extensive operations or market capitalization compared to larger entities.
• The executive compensation section details significant stock option grants, some of which are performance-based, but the actual achievement of these milestones is not detailed in this proxy statement.
• The company's stock is not listed on the Nasdaq Stock Market, which may affect liquidity and investor perception.

Risks

• The company's financial statements for the fiscal year ended December 31, 2024, included an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern.
• The company's ability to attract and retain high-performing executives is a stated objective, implying a potential risk if such retention is not successful.
• The company's reliance on equity incentives for executive and director compensation carries the inherent risk associated with stock price volatility.
• The company's governance structure, while having independent committees, is led by a CEO who also serves as Chairman, which can present potential conflicts or reduce independent oversight depending on the specific dynamics.

Future Outlook

The filing does not contain specific forward-looking financial guidance. However, it outlines upcoming proposals for the Annual Meeting, including the election of directors and ratification of auditors for the fiscal year ending December 31, 2026, and the company's ongoing compensation practices.

Management Comments

• The Board of Directors recommends that you vote FOR the election of each of the nominees of the Board of Directors as a Director of Harvard Apparatus Regenerative Technology, Inc.
• The Board of Directors recommends that you vote FOR the proposal to ratify the appointment of CBIZ CPAs P.C. as our independent registered public accounting firm for the fiscal year ending December 31, 2026.
• The Board of Directors recommends that you vote FOR the non-binding approval of the compensation of our named executive officers as disclosed in this proxy statement.
• While our Board of Directors currently believes that separating the roles of Chief Executive Officer and Chairman contributes to an efficient and effective board, such Chairman and Chief Executive Officer roles will be combined until the Board of Directors determines otherwise.
• The Board of Directors has adopted a Code of Business Conduct and Ethics, which applies to all Directors, officers and employees of our Company and its subsidiaries including, without limitation, the Chairman of the Board, Chief Executive Officer, the President, Chief Scientific Officer, as well as the Chief Financial Officer.

Industry Context

StockSavvy.ai notes that this filing is typical for a publicly traded company preparing for its annual shareholder meeting, focusing on governance and executive compensation. The inclusion of a going concern note in the prior year's audit report is a significant point of attention for investors in the biotechnology and regenerative technology sectors, which often face capital-intensive development cycles and regulatory hurdles.

Comparison to Industry Standards

• The company's director compensation, which includes stock options valued at $20,000-$25,000 annually, is generally in line with smaller public companies, though specific benchmarks would require comparison to companies of similar size and sector.
• The executive compensation structure, with base salaries and equity awards, is standard. However, the 'Pay Versus Performance' table shows a significant divergence between 'Compensation Actually Paid' and 'Shareholder Return' in 2024, with a substantial negative shareholder return (-254,472) and high compensation paid, which may not align with industry best practices for linking pay to performance.
• The company's reliance on equity compensation for both executives and directors is a common practice across the biotechnology and technology sectors to align incentives with long-term value creation.

Corporate Governance

Related Party Transactions

• On April 13, 2026, the Company entered into a loan arrangement with Junli He (Chairman and CEO) for $300,000, with interest at 8% annually. The loan is due on the earlier of the closing of the Company's next capital raise of at least $5,000,000 or April 13, 2027. The Audit Committee approved this transaction.
• Previously, on February 1, 2024, the Company entered into a similar loan arrangement with Junli He for $500,000, which was settled in full on August 29, 2024.

Stakeholder Impact

• Shareholders: The election of directors and the advisory vote on executive compensation directly impact shareholder governance and alignment. The potential capital raise mentioned in the loan terms could dilute existing shareholders if not structured favorably.
• Management and Employees: Executive compensation and equity awards are detailed, impacting their incentives and financial well-being. The company's going concern note may create uncertainty.
• Auditors: The ratification of CBIZ CPAs P.C. as auditors is a key decision for financial reporting integrity.

Next Steps

• Stockholders are to vote on the election of three directors.
• Stockholders are to ratify the appointment of CBIZ CPAs P.C. as independent registered public accounting firm for fiscal year 2026.
• Stockholders are to vote on a non-binding advisory basis on the compensation of named executive officers.
• The company will hold its Annual Meeting of Stockholders on June 18, 2026.

Key Dates

Recommendation

This filing is a routine proxy statement for an annual meeting and does not contain new financial performance data or significant strategic shifts. While the company's governance structure and executive compensation are detailed, the prior year's audit report included a 'going concern' note, indicating potential financial instability. The upcoming capital raise also presents uncertainty. Therefore, a 'hold' recommendation is appropriate pending further clarity on financial performance and the outcome of the capital raise.

Keywords

Proxy Statement, Annual Meeting, Stockholders, Directors, Executive Compensation, Independent Auditors, Corporate Governance, Equity Awards, SEC Filings, Harvard Apparatus Regenerative Technology